A single-nucleotide polymorphism (SNP) in the promoter of the Mdm2 gene (Mdm2 SNP309-G ) results in an increased Mdm2 expression, partial attenuation of the p53 pathway and accelerated tumor development. Clinical case-control studies indicate the Mdm2 SNP309-G allele associates with a significant increase in colorectal cancer (CRC) risk that is heightened in women, but the biological significance of this polymorphism has never been directly evaluated. To examine whether the Mdm2 SNP309-G allele contributes to colorectal cancer, we generated cohorts of mice harboring either the G (minor allelic variant) or T (major allelic variant) allele and treated them with azoxymethane (AOM), a carcinogen that induces sporadic colorectal cancer. Mdm2 SNP309-G/G mice displayed a significant reduction in survival following AOM treatment with more colonic lesions in a wider distribution throughout the lower and upper colon and an attenuated apoptotic response following exposure. AOM did not significantly induce stabilization of wild-type p53 or activate p53 downstream targets following AOM treatment, regardless of the genotype. Instead, Mdm2 SNP309-G/G colons had significant changes in the expression of genes that regulate Mdm2 transcription (ERα and Sp1) as well as downstream targets of Mdm2. Together these results suggest the Mdm2 SNP309-G allele significantly impacts CRC through mechanisms outside the p53 pathway.
INTRODUCTION
Colorectal cancer (CRC) is the fourth leading cause of cancerrelated death in the United States. 1 Numerous genetic alterations have been identified that cooperate to drive the development of this malignancy. For instance, amplification and overexpression of Mdm2-an E3 ubiquitin ligase well known for its role in regulating the tumor suppressor p53-are observed in 25% of cases. 2 Recent studies have revealed that even subtle changes in Mdm2 expression can alter cancer phenotypes. [3] [4] [5] A decade ago, a high frequency single-nucleotide polymorphism (SNP) that results in a T-to-G nucleotide change in the first intron of MDM2 (SNP309) was identified. 6 The polymorphic G allele creates an enhanced Sp1-binding site in the second promoter of MDM2, leading to a 22% increase in binding efficiency of the transcription factor Sp1 and higher Mdm2 protein levels. 7 Clinical and animal model studies demonstrate that carrying the G allele is sufficient to induce malignant phenotypes in a number of different tissues, including the colon. 5, 6, 8, 9 Given the well-established connection between Mdm2 and p53, 10 much of the research on the Mdm2 SNP309-G allele has focused on its interaction with the p53 pathway. 11 However, Mdm2 has also been shown to influence tumor phenotypes though p53independent mechanisms. 12 For example, in CRC, several studies link the Mdm2 SNP309-G allele to exacerbated tumor phenotypes and increased overall risk, specifically in pre-menopausal women. 8, 9 Importantly, this Mdm2 SNP309-G -associated risk is lost in women once they are post-menopausal. Furthermore, the gender difference is not limited to the colon, as women harboring the Mdm2 SNP309-G allele have an increased risk of developing other cancers, including B-cell lymphoma, melanoma and lung cancer. [13] [14] [15] Together these findings strongly suggest that female-specific hormones such as estrogen and/or associated signaling pathways may exacerbate the impact that the Mdm2 SNP309-G allele has on cancer phenotypes. Although the mechanisms governing the interaction between Mdm2 and hormonal regulation have not been fully elucidated, tumorigenic phenotypes may be influenced by estrogen response elements that reside in close proximity to the polymorphic Sp1-binding site. 16 These estrogen response elements allow estrogen receptors and Sp1 to preferentially increase Mdm2 expression in a Mdm2 SNP309-G -dependent manner. 17, 18 Azoxymethane (AOM) is a genotoxic carcinogen commonly used to induce sporadic CRC due to its high potency and its ability to reproducibly mimic characteristics of human CRCs, such as the progression from aberrant crypt foci (ACFs) to polyps to adenoma/ adenocarcinomas. 19 Even though AOM has been used in numerous animal model studies, its impact on some biological processes is not fully understood. For instance, there is conflicting evidence on the role of p53 in AOM-induced CRC. Previous studies have shown that p53 has a gene dosage-dependent effect on AOM-induced CRC, 20 yet AOM-induced tumors inconsistently stabilize p53, and do not activate p53-dependent targets. 20, 21 Although the impact that p53 has on AOM-induced CRC remains unclear, AOM has a documented relationship with estrogen signaling pathways, and specifically with estrogen receptor alpha (ERα). Estrogen has been demonstrated to promote tumorigenesis in AOM mouse models 22 and other studies have shown a dramatic increase in ERα expression in tumorous tissue after AOM treatment. 23 In this study, we used AOM to induce sporadic colon cancer in genetically engineered mice harboring either the Mdm2 SNP309-G or Mdm2 SNP309-T allele. AOM-treated Mdm2 SNP309-G/G mice had reduced survival compared with Mdm2 SNP309-T/T mice. In addition, we also observed significant pathological differences as well as a significantly decreased apoptotic response following AOM exposure in Mdm2 SNP309-G/G mouse colons compared with Mdm2 SNP309-T/T colons. The observed differences between the Mdm2 SNP309-G/G and Mdm2 SNP309-T/T cohorts did not appear to be dependent on activation of the p53 pathway, as no stabilization of p53 was detected, nor were p53 canonical targets significantly upregulated. In contrast to the lack of changes in the p53 pathway, ERα and Sp1 were both upregulated in treated colons relative to untreated colons and this increase was significantly higher in the colons of Mdm2 SNP309-G/G mice. These results suggest that the Mdm2 SNP309-G allele amplifies AOM-induced expression of ERα signaling and alters cancer phenotypes through mechanisms outside the p53 pathway.
RESULTS
The Mdm2 SNP309-G allele results in a significant reduction in survival following exposure to AOM Clinical correlation studies demonstrate that the Mdm2 SNP309-G allele associates with increased rates of colon cancer. 8, 24, 25 Likewise, animal studies confirm mice harboring two copies of the Mdm2 SNP309-G allele have an increased proclivity for developing sporadic cancers. 5 To directly evaluate the relationship between Mdm2 SNP309 and colon cancer, we injected cohorts of Mdm2 SNP309-G/G (G/G, n = 33) and Mdm2 SNP309-T/T (T/T, n = 33) mice weekly from 8 weeks of age until 20 weeks of age with 10 mg/kg of AOM and subsequently monitored mice for changes in morbidity and survival. This dose has previously been shown to induce significant colonic changes that often result in sporadic colorectal cancers. 26 Following completion of this treatment regimen, G/G mice displayed a significant reduction in survival compared with T/T mice (Figure 1 , hazard ratio for G/G: 2.728; confidence interval = 2.289-7.303). The median survival of the G/G and T/T cohorts were 211 days (77days post final injection) and 374 days (240 days post final injection), respectively (median difference of 163 days, P o0.0001). AOM-treated wild-type mice (n = 19), which lack the humanized MDM2 P2 promoter, had a median survival similar to T/T mice (324 days), indicating the observed survival difference is specifically due to the presence of the Mdm2 SNP309-G allele. The significant changes in survival were further illustrated by the observation that approximately 45% of mice in the G/G cohort either died or were moribund prior to the first T/T death. These results indicate that the Mdm2 SNP309-G allele greatly impacts survival outcomes following exposure to the carcinogen AOM.
AOM-treated Mdm2 SNP309-G/G mice have increased numbers and distribution of ACFs and colonic polyps AOM exposure induces colonic neoplasms specifically in the lower colon. 26 Thus, to examine how AOM exposure impacts colonic pathology in an Mdm2 SNP309 -dependent manner, we killed moribund AOM-treated Mdm2 SNP309-G/G and Mdm2 SNP309-T/T mice and collected their colons. Pathological analyses were used to quantify ACFs, which are preneoplastic lesions, and discrete adenomatous polyps. A significant increase in ACF number was observed in AOM-treated G/G mice compared with T/T mice (Figure 2a , 92.8% for G/G versus 53.3% for T/T, P = 0.0352). Given that AOM preferentially induces lesions in the lower colon, we also examined ACF intrusion into the upper colon. AOM-treated G/G mice had a significant increase in the number of ACF in the upper colon compared with T/T mice. (Figure 2b , P = 0.0237). In addition, G/G mice displayed a trend toward an increased percentage of mice with visible polyps at time of necropsy (92% of G/G vs 57% of T/T, Figure 2c , P = 0.0768). G/G mice also had a slightly higher rate of developing adenocarcinomas as compared with T/T mice (76.9% of G/G vs 64.3% T/T) ( Supplementary Table 1 ). Importantly, these phenotypic changes were observed despite the significant difference in survival, suggesting that G/G mice develop more neoplasms over a larger area with a significantly shorter latency.
In addition to the colonic phenotypes, G/G and T/T mice also displayed alterations in other organs (Supplementary Table 1 ). As AOM is known to also impair normal liver functions, this complication may have contributed to the observed survival differences. Thus, to more accurately determine the impact that the Mdm2 SNP309 allele specifically has in the colon, we generated a second cohort of G/G (n = 8) and T/T (n = 8) mice that received the same injection regimen as the survival cohort (10 mg/kg AOM intraperitoneal injection once a week from 8 weeks of age to 20 weeks of age). However, at 21 weeks of age, tissues were harvested.
These age-matched cohorts also displayed significant differences that were similar to those observed in the survival cohort. Analysis of 23 926 individual colonic crypts in the lower colon showed that G/G mice had a marked increase in the ratio of ACFs to normal crypts when compared with T/T mice ( Figure 2d ), P = 0.0286, and 2E. G/G mice also had significant advancement of ACFs in the upper colon, as seven out of eight (87.5%) G/G mice had ACF intrusion into the upper colon compared with only two out of eight (25%) in the T/T cohort ( Figure 2f , P = 0.0406). These data indicate that the Mdm2 SNP309-G allele increases incidence and distribution of colonic changes following exposure to AOM.
Mdm2 SNP309-G/G colons have decreased activation of apoptosis following AOM treatment To explore the mechanisms responsible for the decrease in survival and increase in ACF and polyp formation in Mdm2 SNP309-G/G mice, we evaluated the proliferation and apoptosis changes following AOM exposure. We initially examined Ki67 levels and BrdU incorporation in the colons of AOM-treated Mdm2 SNP309-G/G and Mdm2 SNP309-T/T mice but did not observe significant differences ( Supplementary Figures 1A and B ). To evaluate the differences in apoptosis, we performed TUNEL (terminal deoxynucleotidyl transferase dUTP nick end labeling) staining on colonic sections from mice killed 8 h after injection with 15 mg/kg of AOM. We observed that colons of G/G mice had approximately three times fewer apoptotic bodies than the colons of T/T mice (Figure 3a , P = 0.0286), indicating a diminished apoptotic response following exposure to AOM in G/G mice.
To further evaluate the differences in apoptotic phenotypes, we examined the expression of cleaved caspase-3 (a potent executor of apoptosis) in colons of mice injected with 15 mg/kg of AOM. Immunohistochemical analyses of colonic sections from mice killed 8 h after injection did not display a significant difference in cleaved caspase-3 staining between the Mdm2 SNP309-G/G and Mdm2 SNP309-T/T cohorts ( Figure 3b ). However, western blot analysis of colonic lysates revealed that although there was no significant difference in the expression level of cleaved caspase-3 in the colons of both Mdm2 SNP309-G/G and Mdm2 SNP309-T/T mice, the G/G colons had significantly higher amounts of the p20 isoform relative to the p17 isoform ( Figure 3c ). Inactive caspase-3 exists as a 32-kDa proform that is cleaved into an intermediary 20-kDa isoform (p20), which is then processed into the fully active 17 kDa. 27 This observation suggests that full engagement of a cleaved caspase-3-dependent apoptotic response may potentially be delayed or inefficient in the colons of G/G mice. To further characterize the difference in apoptotic responses between G/G and T/T cohorts, we examined cleaved caspase-3 expression in mice killed 2 h after AOM injection and found that at this time point, T/T colons had significantly higher cleaved caspase-3 expression than G/G colons (Figure 3d , P = 0.0286). Together these data indicate that the Mdm2 SNP309-G allele results in attenuation or delay of the apoptotic response following AOM exposure.
AOM treatment alters Mdm2 expression in an Mdm2 SNP309-Gdependent manner, but does not induce p53 stabilization. To investigate the molecular mechanisms responsible for the observed differences between AOM-treated Mdm2 SNP309-G/G and Mdm2 SNP309-T/T mice, we examined Mdm2 expression in the colon. Before treatment, Mdm2 SNP309-G/G and Mdm2 SNP309-T/T mice did not exhibit significant differences in Mdm2 expression ( Figure 4a ). However, AOM-treated G/G mice had approximately 1.5-fold higher Mdm2 mRNA expression than T/T mice (Figure 4a , P = 0.0076).
As Mdm2 is well known to exert much of its influence through altering p53 activity, we next investigated the impact of increased Mdm2 expression on p53 activity in AOM-treated mice. In both the age-matched and survival cohorts, we did not detect significant p53 expression via western blot analyses ( Figure 4b ), and immunohistochemistry revealed that only a minority of cells had low-intensity staining (Figure 4c , upper panels). Postulating that p53 may only stabilize acutely following administration of AOM, we examined p53 expression in the colons of G/G and T/T mice treated with a higher dose of AOM (15 mg/kg) at time points ranging from 0.5 to 8 h. Similar to our observation in the age-matched and survival cohorts, we did not detect significant p53 expression at any of the observed time points by either western blot or immunohistochemistry (Figures 4d and e and Supplementary Figure 2A ). To rule out the possibility that the presence of the humanized MDM2 promoter was stifling a p53 response in our cohorts, we also injected wild-type C57BL/6 mice with 15 mg/kg of AOM and collected colons; no p53 expression was detected in these colons either (Figure 4e ). To determine whether AOM was capable of eliciting any p53 response, we treated mice that carry two functionally inactive mutant copies of p53 (p53 R172H/R172H ) with AOM. 28 AOM treatment resulted in a rapid accumulation of mutant p53 in the colons of these mice (Supplementary Figure 2B ). Together these results suggest that this treatment regime is sufficient to activate a p53 response, but only mutant p53 is capable of stabilization in the colons of C57BL/6 mice.
Mdm2 SNP309-G does not affect expression of p53-dependent targets following AOM treatment Although we did not detect wild-type p53 stabilization in the colons of AOM-treated mice, we were able to readily detect the expression of p21, a canonical p53 target, in immunohistochemical analyses of serial sections of colons from both Mdm2 SNP309-G/G and Mdm2 SNP309-T/T mice (Figure 4c ). This p21 activation was observed in the absence of p53 stabilization, indicating that p53 may not be responsible for the observed p21 activation, similar to previous reports. 21, 29 To determine whether p21 could be activated in the absence of a significant p53 response, we administered AOM to p53 R172H/R172H mice, as these mice carry two copies of functionally inactive p53. Immunohistochemical analysis of colons from these mice also showed significant p21 staining (Supplementary Figure 2C ). Together these results suggest that p21 activation is independent of p53 expression in AOM-treated mouse colons. Given the difference in apoptotic responses to acute AOM administration between Mdm2 SNP309-G/G and Mdm2 SNP309-T/T mice, we also examined the expression of p53-dependent proapoptotic targets. Although p53 was not stabilized in colonocytes following AOM exposure, p53 haploinsufficiency and biallelic deletion has previously been shown to attenuate apoptotic responses following AOM treatment in mice, 20 and even subtle changes in p53 activity can result in tumor phenotypes. 5 Thus, we used quantitative reverse transcriptase PCR analysis to assess potential expression changes in the p53-dependent proapoptotic targets PUMA, Bax and Noxa; however, no significant differences were observed in the colons of G/G and T/T mice from the age-matched cohorts (Figure 4f ). To further investigate the role of p53 and its potential activation of downstream targets, we treated p53 R172H/R172H and wild-type mice with AOM and collected colons. We detected a modest but nonstatistically significant decrease in PUMA, Bax, Noxa and p21 in p53 R172H/R172H mice compared with the wild-type mice ( Supplementary Figure 3 ). Together these results suggest that p53 may only have a limited impact on the observed AOM-induced phenotypes and the Mdm2 SNP309-G allele likely functions through p53-independent mechanisms.
Mdm2 SNP309-G -dependent upregulation of ERα and Sp1 following AOM treatment Untreated Mdm2 SNP309-G/G and Mdm2 SNP309-T/T mice had nearly equivalent levels of Mdm2 expression in their colons and only after AOM treatment did significant differences emerge (Figure 4a ). To investigate the mechanisms controlling this upregulation, we examined the expression changes in transcription factors known to be specifically recruited to the polymorphic Mdm2 SNP309-G promoter: ERα and Sp1. Sp1 and ERα function as transcriptional cofactors that preferentially increase Mdm2 transcription from the Mdm2 SNP309-G allele, 13, 16, 18, 30 and AOM exposure has been shown to increase ERα expression in AOM-derived tumors. 23 In our study, we observed a significant increase in ERα expression in the colons of both Mdm2 SNP309-G/G and Mdm2 SNP309-T/T mice from the age-matched cohorts (Figure 5a ). However, the magnitude of this upregulation was significantly greater in the G/G cohort, as AOM-treated G/G colons had greater expression of both ERα mRNA and protein compared with T/T colons (Figure 5a , P = 0.0011 and 5c). This upregulation did not appear to be gender dependent, but rather AOM dependent, as both males and females of the same genotype had comparable ERα expression. Similar to the expression pattern of ERα, Sp1 expression in untreated G/G and T/T colons was not statistically different. However, following exposure to AOM treatment, Sp1 mRNA and protein levels were significantly upregulated in G/G mouse colons compared with T/T colons (Figure 5b) , P = 0.0086 and 5C, indicating that in addition to ERα, in this setting, AOM exposure upregulated Sp1 expression in the colons of Mdm2 SNP309-G/G mice.
To determine if the Mdm2 SNP309-G -dependent upregulation of ERα and Sp1 translated into downstream effects, we examined expression changes in targets of ERα-mediated transcription. Cyclin E, a cell cycle regulator, 31 and steroid receptor coactivator-3 (SRC-3), a transcriptional coactivator involved in inhibiting apoptotic responses, 32 were significantly increased in Mdm2 SNP309-G/G mice compared with Mdm2 SNP309-T/T mice following AOM treatment (Figure 5d , P = 0.0369 and P = 0.0228, respectively, and Supplementary Figure 4 ). Together these findings suggest that Mdm2 SNP309-G magnifies AOM-induced changes in ERα and Sp1 expression to alter ERα signaling and influence tumor phenotypes.
The Mdm2 SNP309-G allele alters FoxO expression after AOM treatment To further examine potential changes in targets other than p53 that may influence the observed phenotypes, we next evaluated the expression level of the FoxO family of transcription factors, as they are targets of Mdm2-dependent ubiqutination and act as tumor suppressors in a variety of cancers, including CRC. [33] [34] [35] Colons from AOM-treated age-matched Mdm2 SNP309-G/G mice had significantly reduced FoxO1 and FoxO3 protein levels when compared with Mdm2 SNP309-T/T mice (Figure 6a ). Importantly, FoxO1 and FoxO3 mRNA levels were not significantly altered in the colons of these mice (Figure 6b ), suggesting the difference in FoxO protein levels is mediated by posttranslational mechanisms, such as ubiquitination by Mdm2. Given the decreased FoxO levels in Mdm2 SNP309-G/G mice, we next examined expression changes in apoptotic genes modulated by FoxOs. Hypoxia-inducible factor 1-alpha (Hif1-α), which is negatively regulated in a FoxOdependent manner, was upregulated in G/G mouse colons (Figure 6c , P = 0.002). This result is similar to the observed FoxOmediated expression of Hif1-α in cell line studies. 36 Furthermore, TRAIL, a proapoptotic target that is transcriptionally regulated through FoxO-dependent and independent mechanisms, 37 was significantly upregulated following AOM treatment in T/T colons compared with the colons of G/G mice (Figure 6c , P = 0.0344) Together these results suggest that the Mdm2 SNP309-G allele impacts colonic phenotypes through mechanisms outside of the p53 pathway.
DISCUSSION
Clinical correlational studies and meta-analyses indicate the Mdm2 SNP309-G allele associates with an increased risk of developing colorectal cancer, particularly in women. 8, 13, 24, 25 To directly examine the impact that the Mdm2 SNP309-G allele has on CRC, we generated two genetically engineered mouse models carrying the humanized MDM2 intron 1 harboring either the major (T) or minor (G) allelic variant. Importantly, the humanized intron used in this study is homozygous for the Mdm2 SNP285-G allelic variant, which does not interfere with Sp1 activities at the Mdm2 SNP309-G site. 7 These cohorts were treated with AOM, a carcinogen commonly used to induce sporadic colorectal cancer. Using this model, we demonstrate that the presence of the Mdm2 SNP309-G allele significantly alters Mdm2 expression, colonic architecture and profoundly reduces survival in AOM-treated Mdm2 SNP309-G/G mice. In agreement with previously reported studies, AOM treatment did not stabilize p53 or incite robust activation of the p53 pathway in colons of either Mdm2 SNP309-G/G or Mdm2 SNP309-T/T mice. However, even though no detectable difference in the p53 pathway was observed in our mouse models, we cannot rule out a possible interplay between the MDM2 SNP309-G allele and p53 in human CRCs as p53 gene dosage has been shown to impact tumor formation in AOM models and affect apoptotic responses, even in the absence of p53-dependent target activation. 20 It is also possible that p53 expression does not need to achieve a level necessary for detection by western blot and immunohistochemistry to affect colonic phenotypes. Thus, the Mdm2 SNP309-G allele may yet have further impacts on the p53 pathway that are not predicted by this model system.
However, based on our experimental findings in this setting, the phenotypes observed in MDM2 SNP309-G/G mice are likely resultant from p53-independent mechanisms. In our model, we saw significant ERα, Sp1 and Mdm2 upregulation in colons of MDM2 SNP309-G/G mice compared with colons of MDM2 SNP309-T/T mice after AOM exposure. These differences in the expression were not observed in the colons of untreated mice, indicating that AOM was likely the trigger for these changes. Though previous studies have reported a significant increase in ERα expression following AOM exposure, 23 we observed a particularly striking increase in ERα expression specifically in the colon of G/G mice: a 9.3-fold increase in G/G colons compared with a 3.7-fold increase in T/T colons. As ERα is capable of directly cooperating with Sp1 to drive transcription, 38, 39 it is likely that the increase in ERα and Sp1 levels induced an increase in Mdm2 transcription through the Sp1-binding site enhanced by the Mdm2 SNP309-G allele.
Although these studies provide a means for ERα to upregulate Mdm2 at through the polymorphic Sp1 promoter, they fail to explain why we observe significant Mdm2 SNP309-G -dependent upregulation of ERα, Sp1, and other ERα-related targets. However, previous studies investigating the relationship between Mdm2 and ERα provide insight into these observations. Mdm2 has been shown to enhance ERα transcriptional activity either through direct interaction or by increasing its turnover rate. 40, 41 Given this, it is plausible to envision that the changes in expression we observe are the result of a self-reinforcing feedback loop in which AOM triggers ERα upregulation, ERα stimulates Mdm2 production and Mdm2 enhances ERα activity.
Regardless of the potential feedback mechanism, the increased ERα/Sp1 levels in Mdm2 SNP309-G/G mouse colons suggests that female Mdm2 SNP309-G/G mice may experience exacerbated phenotypes compared with male mice. In fact, our results demonstrate a trend toward shorter survival in female G/G mice compared with male G/G mice (62-day decrease in median survival, P = 0.0829) that was not observed in the T/T cohort (14-day difference in median survival between the two genders, P = 0.3849). However, we did not observe a significant difference in ERα expression between genders within the same cohorts nor was there a notable difference in ACF or polyp formation. Although it is conceivable that our cohorts were simply not large enough to achieve statistical significance, it is more likely that the lack of statistical difference between genders in the G/G cohort was not driven by female hormones, but rather AOM-induced ERα activity, which would diminish observable differences.
ERα signaling is known to have a bevy of both pro-and antitumorigenic effects, but the one significantly altered program that we observed in our mouse model was a divergence in apoptosis and cleaved caspase-3 expression. ERα has been demonstrated to increase the expression of prosurvival genes and repress proapoptotic targets, even in the absence of exogenous estrogen. 42, 43 This is echoed in our model, as we observed significantly higher expression of SRC-3 and Cyclin E, which are ERα-mediated transcriptional targets that attenuate apoptotic responses or regulate the cell cycle, respectively. 9, 31, 32 Furthermore, our observed differences in cleaved caspase-3 processing in the colons of Mdm2 SNP309-G/G mice may also be attributed to elevated ERα expression, as overexpression of ERα has been implicated in attenuating cleaved caspase-3-dependent activities. 43 However, the apoptotic differences observed in colons of the G/G mice may also be influenced by Mdm2 downstream effects, as we observed an Mdm SNP309-G -dependent change in FoxO expression. FoxO proteins control the expression of several proapoptotic genes, including TRAIL, which was significantly downregulated in the colon of G/G mice. Collectively, these findings support the notion that the Mdm2 SNP309-G allele may influence cellular processes, such as apoptotic responses, through mechanisms outside of the p53 pathway following carcinogeninduced colonic injury.
Much of our collective understanding of how Mdm2 regulates the development of precancerous lesions to frank malignancies is framed through the prism of the Mdm2/p53 feedback loop. However, recent studies have demonstrated that this feedback loop is descendible in some settings. 4 Thus, we propose that in the absence of a marked p53 response, there may exist additional pathways that the Mdm2 SNP309-G allele can exert its influence through. In this study, we demonstrate that the Mdm2 SNP309-G allele contributes to colonic phenotypes independently of p53 pathway activation by enhancing ERα and Sp1 expression and repressing FoxO expression following exposure to AOM. The interaction between the Mdm2 SNP309-G allele and ERα is of particular interest as it may provide a rationale as to how the Mdm2 SNP309-G allele eliminates the protective effect of estrogen in CRC in women. However, to fully evaluate this relationship, additional studies are necessary to further elucidate the role of Mdm2 SNP309-G in oncogenesis.
MATERIALS AND METHODS

Mouse strains
Generation of Mdm2 SNP309-G/G , Mdm2 SNP309-T/T and p53 R172H/R172H mice have been previously described. 5, 28 All mice, including wild-type mice, were maintained on a C57BL/6 background. Animal studies were performed according to IACUC and MD Anderson guidelines.
AOM treatment of mouse cohorts
Wild-type, Mdm2 SNP309-G/G , Mdm2 SNP309-T/T and p53 R172H/R172H mice cohorts were treated with AOM via intraperitoneal injection according to the following dose schedules: Short-term cohorts were injected at 35 days of age with 15 mg/kg of AOM, and then necropsied at indicated time points post injection. Mice from the wild-type, Mdm2 SNP309-G/G and Mdm2 SNP309-T/T age-matched and survival cohorts were injected weekly with 10 mg/kg of AOM from 8 to 20 weeks of age (12 injections). Age-matched cohorts were killed 1 week after final treatment (21 weeks of age) and tissues were collected. Survival cohort members were killed and necropsied when moribund.
Tissue collection and histology
Tissues were harvested from mice at specific time points or when moribund. Collected tissues were fixed in 10% phosphate-buffered formalin and embedded in paraffin or flash frozen in LN 2 for protein or RNA analyses. For formalin-fixed colons, these tissues were either mounted on glass slides (for ACF counting) or swiss-rolled prior to fixation. Serial sections were stained with hematoxylin and eosin and subjected to pathological analyses by a board-certified veterinary pathologist in the Department of Veterinary Medicine and Surgery.
RNA analysis
Total RNA from mouse tissues was extracted as previously described. 5 First-strand synthesis was performed using iScript RT (Biorad, Hercules, CA, USA). The resulting cDNAs were amplified by quantitative reverse transcriptase PCR using primers for p21, 5 Mdm2, 44 Puma, 45 Noxa, 45 Bax, 45 ER-α, 46 Trail, 45 FoxO 1, 45 FoxO3 45 and Rplp0. 5 Individual samples were performed in triplicate and the expression of mRNA was normalized to RPLP0. Analysis of Ccne2, Hif1-α, SRC-3 and Sp1 expression was performed using a predesigned quantitative reverse transcriptase PCR plate from Biorad.
Immunoblotting analysis
Proteins were extracted and analyzed as previously described. 47 Protein concentrations were determined by Bradford assays, loaded equally onto SDS-polyacrylamide electrophoresis gels. SDS-polyacrylamide electrophoresis gels were equally loaded with 35-100 μg/lane of soluble extract depending on protein of interest. For evaluation of p53 expression, 50 μg/lane of soluble extract was typically loaded. Primary antibodies are summarized in Supplementary Table 2 . Antibodies and antigen-antibody complexes were detected using an enhanced chemiluminescence kit (GE Healthcare, Buckinghamshire, UK) or BCIP/NBT Color Development Substrate (Santa Cruz Biotechnology, Dallas, TX, USA). The ratio of the 20-kDa isoform of cleaved caspase-3 (p20) to the 17-kDa isoform (p17) was determined by comparing the intensity of p20 (numerator) with p17 (denominator) using densitometry analysis. The median value between the Mdm2 SNP309-T/T samples was arbitrarily set to a value of 1, and then compared with the relative median of the Mdm2 SNP309-G/G samples. Similarly, changes in ERα and Sp1 expression were determined by comparing the ratio of each protein with β-actin within a single sample and then arbitrarily setting one Mdm2 SNP309-T/T sample to a value of 1. Protein expression levels for the remaining Mdm2 SNP309-T/T and Mdm2 SNP309-G/G lanes were then compared against the ratio of the single Mdm2 SNP309-T/T sample set to a value of one (1.00).
Immunohistochemistry
Immunohistochemistry was performed as previously described. 48 Epitope exposure was performed in pH 9.0 Tris-buffer (for p21) or pH 6.0 citric acid buffer (all other antibodies). Counterstain was Nuclear Fast Red. Primary antibodies are summarized in Supplementary Table 2 . TUNEL staining was performed as directed with the FragEL DNA Fragmentation Detection Kit (Millipore, Darmstadt, Germany). BrdU staining was performed in accordance with the BrdU Labeling Protocol (Life Technologies, Grand Island, NY, USA). Briefly, mice were injected with 15 mg/kg of AOM followed 4.5 h later by a 1.5-h pulse of BrdU according to the manufacturer's protocol. Mice were then killed and colons collected.
Statistical analysis
Analysis was performed using GraphPad Instat software (GraphPad Software, Inc., La Jolla, CA, USA). Significance was determined by Mann-Whitney U-tests or Fisher's exact test for comparisons between two groups. Survival curves were plotted using the Kaplan-Meier method and compared by the log-rank (Mantel-Cox) test using GraphPad Prism. All P-values were two sided and the level of statistical significance was set at o0.05.
